CTI BIOPHARMA CORP: key financial figures for fiscal year 2022 (in USD), standardized from XBRL/iXBRL filings by Hub-Equity:
- Revenue (FY2022)
- $53.9M
- Net Income/Loss (FY2022)
- -$93.0M
- Total Assets (FY2022)
- $125.9M
- Total Equity (FY2022)
- -$17.6M
- Cash Flows from Operating Activities (FY2022)
- -$81.2M
Source: CTI BIOPHARMA CORP 10-K filing (FY2022). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.
